Novartis AG operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Novartis with three other
pharmaceutical manufacturers in Europe:
sales of 36.20 billion Euro [US$42.24 billion]
of which 83%
Roche Holding Aktiengesellschaft
(53.30 billion Swiss Francs [US$55.12 billion]
of which 77%
was Pharmaceuticals), and
based in Germany
(35.02 billion Euro [US$40.86 billion]
of which 48%
was Pharmaceuticals & Biological Products).
Novartis reported sales of 49.16 billion Swiss Francs (US$50.83 billion)
December of 2017.
a very small
increase of 0.7%
versus 2016, when the company's sales were 48.83 billion Swiss Francs.
The sales level in 2017 was fairly close to the level five years ago: in 2012, Novartis had sales
of 52.86 billion Swiss Francs.
Sales of Alcon saw an increase
that was more than double the company's growth rate: sales were up
2.8% in 2017, from
5.75 billion Swiss Francs to 5.91 billion Swiss Francs.
Not all segments of Novartis experienced an increase in sales in 2017:
sales of Sandoz fell 1.7% to 9.86 billion Swiss Francs.